- ✓Average weight loss: ~15% (semaglutide) vs ~21% (tirzepatide) in clinical trials
- ✓How the side-effect profiles actually differ week to week
- ✓A decision framework based on your goal, budget, and tolerance
The core difference
Semaglutide (the molecule in Ozempic and Wegovy) activates the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) is a dual agonist — it activates both the GLP-1 and GIP receptors. In clinical trials, that dual mechanism translates to higher average weight loss: roughly 21% at top tirzepatide doses versus roughly 15% for semaglutide.
Higher average results do not automatically make tirzepatide the right choice for everyone. Cost, tolerance, and titration speed all matter.
Side effects, week by week
Both medications share the same core side-effect profile — nausea, constipation, and reduced appetite are most common, and most are mild and improve with slow dose titration. Tirzepatide users sometimes report a slightly smoother appetite-suppression curve; semaglutide has a longer real-world track record.
The single biggest predictor of a tolerable experience is titration speed. Rushing to a higher dose is the most common cause of dropping out.
How to decide
Choose tirzepatide if maximum weight loss is the priority and your budget and tolerance allow it. Choose semaglutide if you want the longest track record, a typically lower price point, or you tolerate it better. Either way, a provider that includes clinical evaluation will help you match the molecule to your history.
Want the full version — printable, with the complete checklists and benchmark tables? Grab the free PDF using the form.